Clinical Trials Browser

Phase 2 × ALT-803 × CNS × Clear all

NCT06061809 2026-02-12

N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma

Phase 2 Recruiting

Glioblastoma